Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.
AffiliationSchool of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, United Kingdom.
MetadataShow full item record
AbstractThe conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Early-phase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients.
CitationRadioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. 2009, 11 (5):363-70 Curr Oncol Rep
JournalCurrent Oncology Reports
- Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
- Authors: Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A
- Issue date: 2009
- Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
- Authors: Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A
- Issue date: 2009
- Radioimmunotherapy in follicular lymphoma: some like it hot….
- Authors: Kersten MJ
- Issue date: 2011 Apr
- Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies.
- Authors: Park SI, Press OW
- Issue date: 2007 Nov
- Radioimmunotherapy for Non-Hodgkin's Lymphoma.
- Authors: Rao AV, Akabani G, Rizzieri DA
- Issue date: 2005 Aug